Filing Analysis
Atara Biotherapeutics, Inc. announced its second quarter 2026 financial results and operational progress on August 12, 2026. The filing serves as a formal notice of the release of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Announcement date: August 12, 2026.
- The filing includes a press release titled 'Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress' as Exhibit 99.1.
- Interim CFO Kevin G. Sarney signed the report.
Atara Biotherapeutics announced the departure of its Chief Accounting Officer, Yanina Grant-Huerta, effective July 17, 2026. The company has appointed Kevin G. Sarney as interim CFO and principal financial/accounting officer via a consulting agreement with Charles River CFO, Inc.
🚩 Red Flags
- Simultaneous departure of the Chief Accounting Officer and appointment of an interim CFO suggests potential volatility in financial leadership.
- Use of an interim consultant for both CFO and Principal Accounting Officer roles can sometimes indicate a transition period or internal restructuring.
📋 Key Facts
- Chief Accounting Officer Yanina Grant-Huerta will end employment on July 17, 2026.
- Kevin G. Sarney appointed as interim Chief Financial Officer (CFO) effective June 26, 2026.
- Mr. Sarney will also serve as the Company's principal financial officer and principal accounting officer.
- The CFO appointment is via a consulting agreement with Charles River CFO, Inc. (CRCFO).
- Compensation for Mr. Sarney is paid to CRCFO at an hourly rate rather than direct salary from Atara.
Atara Biotherapeutics announced the appointment of Brian Cherry to its Board of Directors and Audit Committee, and reported the results of its 2026 Annual Meeting of Stockholders.
📋 Key Facts
- Brian Cherry appointed as Class I director and member of the Audit Committee effective June 11, 2026.
- Mr. Cherry received an initial equity award of 24,000 restricted stock units vesting over three years.
- Mr. Cherry will receive an annual cash retainer of $55,000.
- Stockholders elected AnhCo Nguyen Ph.D. and Nachi Subramanian to the Board until 2029.
- Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase reserved common stock by 400,000 shares.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
Atara Biotherapeutics announced its financial results for the first quarter ended March 31, 2026, and provided an update on operational progress.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 12, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The filing includes Exhibit 99.1, a press release titled 'Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress'.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Atara Biotherapeutics provided a regulatory update following a Type A meeting with the FDA regarding the Complete Response Letter (CRL) for its EBVALLO™ Biologics License Application. The meeting aimed to address issues raised by the FDA in the CRL issued on January 9, 2026.
🚩 Red Flags
- The company is currently managing a Complete Response Letter (CRL), which signifies a failure to obtain FDA approval in the initial review cycle.
- Regulatory delays for lead assets can significantly impact the cash runway of micro-cap biotech companies.
📋 Key Facts
- The company held a Type A meeting with the FDA to discuss the CRL for tabelecleucel (EBVALLO™).
- The CRL was originally issued by the FDA on January 9, 2026.
- The update was communicated via a press release on May 7, 2026.
- EBVALLO™ is a primary product candidate for the company.
Atara Biotherapeutics received a notice from Nasdaq on April 30, 2026, for failing to maintain the minimum $50 million market value of listed securities (MVLS) required for the Nasdaq Global Select Market. The company has 180 days, until October 27, 2026, to regain compliance by maintaining a $50 million MVLS for at least 10 consecutive business days.
🚩 Red Flags
- Market capitalization has fallen below the $50 million threshold for a sustained period (30 days).
- Potential for delisting from the Nasdaq Global Select Market if compliance is not regained.
- The notice reflects a significant decline in the company's equity valuation.
📋 Key Facts
- Notice received from Nasdaq on April 30, 2026, regarding non-compliance with Nasdaq Listing Rule 5450(b)(2)(A).
- The Company's market value of listed securities (MVLS) was below $50 million for 30 consecutive business days.
- The compliance deadline to regain the $50 million MVLS threshold is October 27, 2026.
- To regain compliance, MVLS must close at $50 million or more for a minimum of 10 consecutive business days.
- The Company is considering options including a transfer to The Nasdaq Capital Market.
Atara Biotherapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made via a press release furnished as Exhibit 99.1.
📋 Key Facts
- Financial results announced on March 16, 2026, for the fiscal year ended December 31, 2025.
- The filing includes Item 2.02 for Results of Operations and Financial Condition.
- The press release is titled 'Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress'.
- Yanina Grant-Huerta, Chief Accounting Officer, signed the report.
Atara Biotherapeutics announced that the FDA has scheduled a Type A meeting to discuss the Complete Response Letter (CRL) issued on January 9, 2026, regarding the Biologics License Application (BLA) for tabelecleucel (tab-cel). The meeting, conducted with partner Pierre Fabre Pharmaceuticals, aims to resolve issues raised in the CRL and establish a path for BLA resubmission.
🚩 Red Flags
- The underlying cause of this filing is a Complete Response Letter (CRL), which represents a formal FDA rejection of the current BLA.
- The requirement for 'additional efficacy data' suggests the initial clinical data package was insufficient for approval.
- The company is reliant on a third-party partner (Pierre Fabre) to lead the regulatory interaction.
📋 Key Facts
- The FDA scheduled a Type A meeting to discuss the CRL for tabelecleucel (tab-cel) issued on January 9, 2026.
- The BLA is held by Atara's partner, Pierre Fabre Pharmaceuticals.
- The meeting will focus on addressing CRL points and incorporating additional efficacy data collected since the original submission.
- Atara expects to provide a further regulatory update in the second quarter of 2026.
- Tab-cel (EBVALLO) is an allogeneic T-cell immunotherapy targeting EBV+ PTLD.
Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, has requested a Type A meeting with the FDA to address issues raised in a January 2026 Complete Response Letter (CRL) for EBVALLO™.
🚩 Red Flags
- The FDA previously issued a Complete Response Letter (CRL) on January 9, 2026, which is a formal rejection of the current application.
- Type A meetings are typically reserved for stalled product development or to discuss critical path issues, indicating significant regulatory hurdles.
📋 Key Facts
- Pierre Fabre Pharmaceuticals submitted a request for a Type A meeting with the FDA on March 3, 2026.
- The meeting aims to discuss the plan to address issues from the CRL issued by the FDA on January 9, 2026.
- The regulatory update concerns the Biologics License Application (BLA) for Tabelecleucel (EBVALLO™).
- The filing is categorized under Item 8.01 (Other Events).
Atara Biotherapeutics (ATRA) filed an 8-K on February 23, 2026 disclosing an amendment to its Purchase and Sale Agreement with HCR Molag Fund, L.P., deferring a $9.0 million milestone payment obligation from June 30, 2026 to January 1, 2028. In exchange for this deferral, the Company issued HCR a warrant to purchase up to 400,000 shares of common stock at a near-zero exercise price of $0.0001 per share, representing a significant equity concession. The filing covers three 8-K items simultaneously, suggesting financial pressure and a need for near-term cash relief.
🚩 Red Flags
- Near-zero exercise price warrant ($0.0001/share) issued to a creditor/financial partner signals the company lacked cash or alternative leverage to negotiate better terms
- Inability to meet a $9.0 million milestone payment by June 30, 2026 implies potential liquidity stress — requiring an 18-month extension
- Multiple 8-K items in a single filing (1.01, 3.02, 8.01) is a red flag escalator per analytical guidelines
- Issuance of unregistered equity securities (Item 3.02) to a lender/fund in exchange for debt relief raises related-party and dilution concerns
- Warrant has no expiration date, creating permanent dilution overhang of up to 400,000 shares
- HCR Molag Fund relationship spans back to 2022 Purchase and Sale Agreement, suggesting ongoing financial entanglement with a single capital provider
📋 Key Facts
- Amendment dated February 20, 2026 to the Purchase and Sale Agreement originally dated December 20, 2022 with HCR Molag Fund, L.P.
- $9.0 million cash milestone payment due date extended from June 30, 2026 to January 1, 2028 — an 18-month deferral
- Milestone is tied to the Amended and Restated Commercialization Agreement dated October 31, 2023 with Pierre Fabre Medicament
- Company issued a warrant to purchase up to 400,000 shares of Common Stock as consideration for the deferral
- Warrant exercise price: $0.0001 per share (effectively a free equity grant)
- Warrant is exercisable immediately with no expiration date
- Beneficial ownership blocker at 4.99% of outstanding shares
- Warrant may be exercised via cashless exercise
- Warrant issued under Section 4(a)(2) exemption (unregistered); Company intends to file a registration statement for resale
- Filing covers Items 1.01, 3.02, and 8.01 — three separate items in a single 8-K
- Signed by AnhCo Thieu Nguyen, President and CEO
Atara Biotherapeutics announced that the FDA issued a Complete Response Letter (CRL) regarding its Biologics License Application for EBVALLO™ (tabelecleucel). The company also provided preliminary year-end 2025 cash and liquidity positions.
🚩 Red Flags
- FDA Complete Response Letter (CRL) indicates the current application for EBVALLO™ was not approved in its present form, requiring additional data or clinical studies.
- Preliminary financial reporting suggests potential volatility in cash position as of year-end 2025.
📋 Key Facts
- FDA issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application on January 12, 2026.
- The company provided preliminary estimates of cash, cash equivalents, and short-term investments as of December 31, 2025.
- EBVALLO™ is the primary asset discussed in the regulatory update.
Atara Biotherapeutics entered into a Fourth Amendment to its Commercialization Agreement with Pierre Fabre Medicament on December 30, 2025. The amendment involves restructuring milestone payments related to the FDA approval of tab-cel.
🚩 Red Flags
- Reduction in guaranteed/potential regulatory milestone value ($40M down to $31M) suggests a renegotiation of terms that may be less favorable for immediate cash certainty.
- The restructuring implies a shift from regulatory-based milestones to commercial-performance-based incentives.
📋 Key Facts
- Date of Amendment: December 30, 2025
- Counterparty: Pierre Fabre Medicament
- Regulatory Milestone Change: Potential BLA approval milestone for 'tab-cel' reduced from $40.0 million to $31.0 million.
- Commercial Milestone Addition: Company gains right to an additional $15.0 million potential milestone payment upon achieving a specific commercial milestone.
Atara Biotherapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025. The filing serves as a formal announcement of operational progress and financial performance via a press release.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Third quarter ended September 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Signed by Yanina Grant-Huerta, Chief Accounting Officer
Atara Biotherapeutics announced a massive workforce reduction on October 6, 2025, impacting approximately 29% of its total headcount. The company intends to retain only about 15 employees to execute its remaining strategic priorities.
🚩 Red Flags
- Extreme downsizing: Retaining only ~15 employees suggests a near-total cessation of operations or a pivot to a shell/holding company structure.
- Significant operational risk associated with the loss of 29% of staff and extreme concentration of remaining personnel.
- Potential liquidity issues implied by the scale of restructuring and focus on 'essential' survival staff.
📋 Key Facts
- Workforce reduction impacts approximately 29% of current employees.
- The Company will retain approximately 15 employees essential for strategic priorities.
- Expected completion date for workforce reduction is January 2026.
- Estimated $1.3 million in severance and related benefits charges expected.
- Approximately 50% of charges relate to salary continuation/wages per California WARN Act.
Atara Biotherapeutics announced a significant restructuring of its Board of Directors, resulting in the voluntary resignation of three directors and a reduction in board size from ten to seven members. This change includes the replacement of the Board Chair.
🚩 Red Flags
- Significant reduction in board size (30% decrease) often signals internal restructuring or shifts in strategic direction.
- Departure of the Board Chair can indicate leadership instability or changes in corporate governance oversight.
📋 Key Facts
- Three directors—Ameet Mallik, Pascal Touchon, and Maria Grazia Roncarolo, M.D.—voluntarily resigned effective September 2, 2025.
- The Board size was reduced from ten (10) to seven (7) members to 'right-size' the board in alignment with current operations.
- Pascal Touchon, who served as Chair of the Board, has been replaced by Gregory A. Ciongoli as the new Board Chair.
- The resignations were characterized as voluntary following a Board assessment of size and composition.
Atara Biotherapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of operational progress and quarterly earnings.
📋 Key Facts
- Report date: August 11, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The company announced financial results and 'operational progress' via a press release (Exhibit 99.1).
Atara Biotherapeutics announced its preliminary cash, cash equivalents, and short-term investment positions as of June 30, 2025. The company also issued a press release providing regulatory and business updates regarding its product, Tabelecleucel (Tab-cel®).
🚩 Red Flags
- Preliminary financial estimates may change as full Q2 results are finalized.
📋 Key Facts
- Report date: July 14, 2025.
- The filing provides preliminary estimates of cash, cash equivalents, and short-term investments as of June 30, 2025.
- Company issued a press release regarding regulatory and business updates for Tabelecleucel (Tab-cel®).
- Financial figures are based on currently available information and are preliminary.
Atara Biotherapeutics held its 2025 annual meeting of stockholders on June 10, 2025. The results included the election of three directors and advisory votes regarding executive compensation frequency and auditor ratification.
📋 Key Facts
- Annual Meeting held on June 10, 2025.
- Three nominees (AnhCo Nguyen, Matthew K. Fust, and Gregory A. Ciongoli) were elected to the Board of Directors until 2028.
- Stockholders approved executive compensation on an advisory basis.
- Stockholders approved a one-year frequency for future non-binding advisory votes on executive compensation.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Atara Biotherapeutics, Inc. entered into an underwriting agreement for a registered direct offering of common stock and pre-funded warrants to raise approximately $16.0 million in gross proceeds.
🚩 Red Flags
- Equity dilution: The issuance of over 1.5 million warrants represents significant potential future dilution for existing shareholders.
📋 Key Facts
- Offering type: Registered direct offering via underwritten agreement with TD Securities (USA) LLC.
- Total expected gross proceeds: Approximately $16.0 million.
- Securities being issued: 834,237 shares of common stock and pre-funded warrants to purchase up to 1,587,108 shares.
- Pricing: Common stock at $6.61 per share; Pre-Funded Warrants at $6.6099 per share.
- Use of proceeds: Funding activities for tab-cel BLA approval, working capital, and general corporate purposes.
- Closing Date: Expected to close on May 16, 2025.
Atara Biotherapeutics announced Q1 2025 financial results and a simultaneous registered direct offering of common stock and pre-funded warrants. The filing also notes the appointment of two new directors tied to institutional investors participating in the offering.
🚩 Red Flags
- Dilutive securities offering: The issuance of over 1.5 million warrants and nearly 834k shares represents significant potential dilution for existing shareholders.
- Related-party director appointments: Two new board members are directly affiliated with the institutional investors participating in the equity financing (Panacea and Redmile).
- Capital raise timing: The simultaneous announcement of Q1 results and a direct offering often suggests an urgent need for liquidity.
📋 Key Facts
- Registered direct offering of 834,237 shares of common stock at $6.61 per share.
- Offering of pre-funded warrants to purchase 1,587,108 shares at $6.6099 per share.
- Underwriters include TD Securities (USA) LLC representing Panacea Venture, Redmile Group, EcoR 1 Capital, and Adiumentum Capital Management.
- Expected closing date for the offering is May 16, 2025.
- Appointment of James Huang (Panacea) and Nachi Subramanian (Redmile) to the Board of Directors, effective upon completion of the offering.
- New directors will serve terms expiring at the 2027 annual meeting.
Atara Biotherapeutics announced a massive workforce reduction impacting approximately 30% of its staff, retaining only about 23 essential employees. The company expects to complete this restructuring by August 2025 and will recognize $1.4 million in severance costs.
🚩 Red Flags
- Extreme downsizing (retaining only ~23 employees) suggests a pivot toward a shell or highly specialized entity, indicating severe liquidity or operational distress.
- Significant reduction in human capital likely impacts R&D and clinical development capabilities.
- Potential for additional unquantified costs related to the restructuring.
📋 Key Facts
- Workforce reduction impacts approximately 30% of current employees.
- The Company plans to retain only ~23 employees essential for strategic priorities.
- Expected completion date for workforce reduction: August 2025.
- Estimated severance and related benefit charges: $1.4 million.
- Charges are primarily one-time cash expenditures.
Atara Biotherapeutics announced that the FDA has lifted the clinical hold on its EBVALLO (tabelecleucel) program, which had been in place since January 2025. The company is also scheduled for a Type A meeting with the FDA to discuss addressing issues from a previous Complete Response Letter.
🚩 Red Flags
- Ongoing regulatory hurdles: The company is still in the process of addressing a Complete Response Letter (CRL) from January 2025.
- History of clinical holds indicates significant previous regulatory friction for their lead program.
📋 Key Facts
- FDA lifted the clinical hold on active Investigational New Drug (IND) applications for EBVALLO (tabelecleucel).
- The clinical hold was originally placed in January 2025.
- The FDA granted a Type A meeting to discuss addressing issues from the January 2025 Complete Response Letter (CRL).
- Event date: May 5, 2025.
Atara Biotherapeutics entered into an amendment to its commercialization agreement with Pierre Fabre, transferring all manufacturing responsibilities and costs for tabelecleucel (tab-cel) to the partner. In exchange for this transfer and cost assumption by Pierre Fabre, Atara agreed to reduce certain future milestone payments.
🚩 Red Flags
- Reduction of future milestone payments indicates a trade-off for immediate operational relief/de-risking.
📋 Key Facts
- Effective date of amendment: March 31, 2025.
- Pierre Fabre assumes all manufacturing and supply responsibilities for tab-cel worldwide at its own cost.
- Pierre Fabre will cover costs related to remediating a third-party manufacturing facility to address FDA requests for the BLA resubmission.
- Atara agreed to reduce certain potential future regulatory and commercial milestone payments in exchange for accelerated transfer of responsibilities.
- The Company is entitled to up to $550.0 million in aggregate additional potential milestone payments upon achieving specific milestones.
- Includes up to $40.0 million in potential regulatory milestones related to FDA BLA approval.
Atara Biotherapeutics announced the departure of its CFO and COO, Eric Hyllengren, effective March 31, 2025. The company has appointed Yanina Grant-Huerta, previously VP of FP&A, as the new Chief Accounting Officer and principal accounting officer.
🚩 Red Flags
- Simultaneous departure of CFO and COO (dual role exit) can indicate internal instability or strategic shifts.
- The transition involves a consulting arrangement which may suggest an unplanned or abrupt exit rather than a standard retirement/resignation.
📋 Key Facts
- Eric Hyllengren (CFO and COO) departing effective March 31, 2025.
- Hyllengren to provide consulting services through July 31, 2025 at an hourly rate.
- Hyllengren will relinquish all vested and unvested stock option awards as part of the separation agreement.
- Yanina Grant-Huerta appointed Chief Accounting Officer and principal accounting officer effective March 31, 2025.
- Grant-Huerta previously served as VP of Financial Planning and Analysis since March 2023.
Atara Biotherapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal announcement of operational progress and fiscal performance via an attached press release.
📋 Key Facts
- Reporting period: Fourth quarter and Full Year ended December 31, 2024.
- Announcement date: March 7, 2025.
- The filing includes a press release titled 'Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress' as Exhibit 99.1.
Atara Biotherapeutics has announced a massive workforce reduction impacting approximately 50% of its employees. This follows the decision to discontinue development and clinical studies for its primary programs, ATA3219 and ATA3431.
🚩 Red Flags
- Massive workforce reduction (50% of staff) indicates severe distress or pivot.
- Discontinuation of core clinical programs (ATA3219/ATA3431) suggests failure of primary R&D pipeline.
- Significant restructuring charges ($3.0M) expected in the near term.
📋 Key Facts
- Workforce reduction impacts approximately 50% of current employees.
- Discontinuation of all development activities for ATA3219 and ATA3431.
- All CAR T clinical studies evaluating ATA3219 are being discontinued.
- Both ATA3219 and ATA3431 programs are being paused.
- Workforce reduction expected to be substantially complete by June 2025.
- Estimated $3.0 million in severance and related benefits charges.
Atara Biotherapeutics announced a massive workforce reduction impacting approximately 50% of its current employees, effective through June 2025. The company expects to incur $7.5 million in severance and related termination benefits.
🚩 Red Flags
- Massive workforce reduction (50% of staff) often signals severe liquidity issues or a pivot in business strategy.
- Significant restructuring charge ($7.5M) impacting near-term cash flow.
- Uncertainty regarding additional unquantified charges related to the reduction.
📋 Key Facts
- Workforce reduction impacts ~50% of total employees.
- Reduction is expected to be substantially complete by June 2025.
- Estimated $7.5 million in total charges for severance and related benefits.
- Charges are primarily one-time cash expenditures.
The FDA has placed a clinical hold on Atara Biotherapeutics' active Investigational New Drug (IND) applications, affecting both the EBVALLO (tabelecleucel) program and ATA3219. This regulatory setback halts development for key programs targeting EBV+ PTLD, non-Hodgkin’s lymphoma, and systemic lupus erythematosus.
🚩 Red Flags
- Regulatory setback: FDA clinical hold on primary drug candidates directly impacts the company's core value proposition.
- Pipeline disruption: The hold affects multiple distinct programs (EBVALLO and ATA3219), suggesting potential systemic issues in trial design or safety data.
📋 Key Facts
- FDA placed a clinical hold on active IND applications as of January 21, 2025.
- The hold affects the EBVALLO (tabelecleucel) program for adult and pediatric patients with EBV+ PTLD.
- The hold also affects ATA3219, an allogeneic CD19-targeted CAR-T therapy for non-Hodgkin’s lymphoma and systemic lupus erythematosus.
Atara Biotherapeutics issued an 8-K to provide a regulatory and business update regarding its product EBVALLO™ (tabelecleucel) and to report preliminary cash/liquidity positions as of December 31, 2024.
🚩 Red Flags
- Financial figures provided are 'preliminary estimates' and may be subject to significant adjustment upon final audit/closing of books.
📋 Key Facts
- Reported date: January 16, 2025
- The filing includes a press release regarding EBVALLO™ (tabelecleucel) regulatory and business updates.
- Company provided preliminary estimates of cash, cash equivalents, and short-term investments as of December 31, 2024.
- Preliminary financial data is subject to change and does not represent a complete view of the Q4 or full-year 2024 results.
Atara Biotherapeutics, Inc. announced the Board of Directors' approval of its Third Amended and Restated Bylaws, effective December 20, 2024.
🚩 Red Flags
- Increased control for management/Board over stockholder meetings (postponement/cancellation rights) and proxy solicitation processes.
📋 Key Facts
- The Board approved the 'Third Amended and Restated Bylaws' on December 20, 2024.
- Revisions include increased authority for the Chair, CEO, and Board to postpone or cancel special meetings of stockholders.
- Establishment of exclusive use of white proxy cards for the Board.
- New procedural requirements for stockholders proposing business at annual meetings.
- Enhanced disclosure/procedural requirements for director nominees.
Atara Biotherapeutics announced the departure of its Chief Legal Officer, Amar Murugan, effective November 8, 2024. The filing also includes the company's third-quarter 2024 financial results.
🚩 Red Flags
- Departure of a key executive (Chief Legal Officer) during a period involving significant manufacturing transitions and regulatory milestones.
📋 Key Facts
- Chief Legal Officer Amar Murugan departed the company on November 8, 2024.
- Mr. Murugan will provide consulting services for up to 10 hours per month through July 11, 2025, at a rate of $250 per hour.
- The departure includes severance benefits as defined in the company's April 26, 2024 Proxy Statement.
- Mr. Murugan is entitled to two potential bonuses of $150,000 each: one upon FDA approval of tabelecleucel and another related to the manufacturing transition of tabelecleucel to Pierre Fabre Medicament or by July 11, 2025.
- The company released its Q3 2024 financial results on November 12, 2024.
Atara Biotherapeutics, Inc. announced the promotion of Eric Hyllengren to Chief Operating Officer (COO), effective October 14, 2024. Mr. Hyllengren will retain his existing role as Chief Financial Officer (CFO).
🚩 Red Flags
- Dual role (CFO and COO) can sometimes indicate a lean management structure or transitional phase, though common in mid-cap biotech.
📋 Key Facts
- Eric Hyllengren appointed as COO on October 14, 2024.
- Hyllengren will continue to serve as CFO in a dual capacity.
- Base salary for the COO role increased to $520,000 per year.
- Mr. Hyllengren has been with the company since August 2018.
- Prior experience includes 15 years at Amgen Inc.
Atara Biotherapeutics announced a $36 million registered direct offering of common stock and pre-funded warrants. The offering includes significant participation from Adiumentum Capital Fund I LP, where the newly appointed director Gregory A. Ciongoli serves as Managing Partner.
🚩 Red Flags
- Related-party transaction: The new director (Gregory A. Ciongoli) is the Managing Partner of a fund (Adiumentum Capital Fund I LP) that is a major participant in this $36 million offering.
- Significant dilution potential: The issuance of pre-funded warrants for up to 3,604,780 shares represents a substantial increase in share count.
📋 Key Facts
- Registered direct offering to raise approximately $36 million in gross proceeds.
- Issuance of 758,900 shares at $8.25 per share and pre-funded warrants for up to 3,604,780 shares at $8.2499 per share.
- Adiumentum Capital Fund I LP is purchasing 758,900 shares and warrants for up to 150,193 shares for a total of $7.5 million.
- Gregory A. Ciongoli appointed to the Board of Directors, effective upon closing of the offering.
- Proceeds are intended for working capital and general corporate purposes.
- Expected closing date is on or about September 5, 2024.
Atara Biotherapeutics announced a leadership transition where CEO Pascal Touchon will step down as CEO on September 9, 2024, to become Chairman of the Board. AnhCo Nguyen, Ph.D., currently EVP and Chief Scientific Officer, has been appointed as the new President and CEO effective September 9, 2024.
🚩 Red Flags
- CEO departure in a micro-cap biotech can signal internal strategic shifts or instability.
- Transition agreement for outgoing CEO includes consulting fees and equity acceleration.
📋 Key Facts
- Pascal Touchon stepping down as CEO/President effective Sept 9, 2024; transitioning to Chairman of the Board.
- AnhCo Nguyen, Ph.D. appointed as new President and CEO effective Sept 9, 2024.
- Dr. Touchon's transition includes a consulting agreement for 12-18 months at $23,000 per month.
- Dr. Nguyen's compensation includes a $650,000 base salary and a target bonus of 60%.
- The filing also includes the announcement of Q2 2024 financial results (furnished via Exhibit 99.1).
Atara Biotherapeutics announced that the FDA has granted priority review for its Biologics License Application (BLA) for tabelecleucel (tab-cel®). The target action date for the application is January 15, 2025.
📋 Key Facts
- FDA accepted BLA for tabelecleucel (tab-cel®) for priority review.
- Product: Tabelecleucel (tab-cel®), an allogeneic EBV-specific T-cell immunotherapy.
- Indication: Treatment of Epstein-Barr virus (EBV) positive Post-Transplant Lymphoproliferative Disease.
- PDUFA target action date: January 15, 2025.
Atara Biotherapeutics, Inc. has implemented a one-for-twenty-five (1:25) reverse stock split effective June 20, 2024. This action follows stockholder approval at the annual meeting held on June 10, 2024.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing compliance regarding minimum bid price requirements).
📋 Key Facts
- Reverse stock split ratio is 1:25.
- Effective date of the split was June 20, 2024, at 12:01 a.m. ET.
- The common stock began trading on a split-adjusted basis under a new CUSIP (046513206) on June 20, 2024.
- No fractional shares or warrants will be issued; instead, stockholders/holders will receive cash payments based on the closing price from the last trading day prior to effectiveness.
Atara Biotherapeutics, Inc. has announced a one-for-twenty-five (1-for-25) reverse stock split of its common stock. The split is expected to be effective on June 20, 2024.
🚩 Red Flags
- Reverse stock split (often used to combat low share prices or avoid delisting).
- Potential signal of liquidity issues or lack of market interest at current price levels.
📋 Key Facts
- The Board of Directors approved a 1-for-25 reverse stock split.
- Effective Date: June 20, 2024, at 12:01 a.m. ET.
- Trading on a split-adjusted basis begins at market open on June 20, 2024.
- Every 25 shares of common stock will be converted into 1 share.
- Fractional shares and fractional warrants will be paid out in cash.
Atara Biotherapeutics held its 2024 annual meeting of stockholders where shareholders approved a significant amendment to the Certificate of Incorporation to authorize a reverse stock split. The split ratio, determined by the Board, will range from 1-for-4 to 1-for-30.
🚩 Red Flags
- Approval of a reverse stock split (1-for-4 to 1-for-30) often indicates a need to boost share price to maintain Nasdaq listing compliance.
- Shareholders rejected the automatic annual increase to the 2024 Equity Incentive Plan, signaling potential investor dissatisfaction with dilution or compensation structures.
📋 Key Facts
- Annual Meeting held on June 10, 2024.
- Stockholders approved an amendment for a reverse stock split with a ratio between 1-for-4 and 1-for-30.
- Directors William K. Heiden and Ameet Mallik were elected to serve until the 2027 annual meeting.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2024.
- The 2024 Equity Incentive Plan was approved, but an automatic annual increase to said plan was rejected by shareholders.
- An adjournment of the meeting was approved to allow for further solicitation if needed to meet voting requirements for the reverse split.
Atara Biotherapeutics announced its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice of the release of quarterly operational and financial progress.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Announcement date: May 9, 2024.
- The company furnished a press release (Exhibit 99.1) detailing financial results and operational progress.
Atara Biotherapeutics, Inc. announced that Board member Eric Dobmeier will not stand for re-election at the upcoming 2024 Annual Meeting of stockholders. Mr. Dobmeier will complete his current term through the meeting date.
📋 Key Facts
- Eric Dobmeier notified the Company on March 26, 2024, that he will not seek re-election to the Board.
- His term expires at the 2024 Annual Meeting of stockholders.
- The departure is not due to any disagreement or dispute with the Board or management regarding operations, policies, or practices.
Atara Biotherapeutics announced its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal notice of the release of operational progress and fiscal performance via an attached press release.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Announcement date: March 28, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial results and operational progress.
Atara Biotherapeutics has finalized a consulting agreement with its former Chief Medical Officer, Dr. Joshi, following his termination due to a reduction in force. The agreement includes monthly fees and a significant performance-based bonus tied to FDA approval of tabelecleucel.
🚩 Red Flags
- Officer departure linked to 'reduction in force' suggests broader cost-cutting or restructuring.
- Contingent compensation ($180,000) tied to a specific regulatory milestone creates potential future liability and aligns executive interests with a single clinical outcome.
📋 Key Facts
- Dr. Joshi's employment as EVP and CMO terminated effective February 2, 2024, as part of a reduction in force.
- A consulting agreement was entered into on February 22, 2024, lasting through January 31, 2025.
- Consulting compensation includes $3,000 monthly plus $300 per hour for hours exceeding a specified limit.
- Outstanding RSUs will continue to vest during the consulting term.
- A contingent payment of $180,000 is owed to Dr. Joshi upon FDA approval of a biologics license application (BLA) for tabelecleucel.
Atara Biotherapeutics received a deficiency notice from Nasdaq for failing to maintain the minimum $1.00 bid price requirement. Simultaneously, the company entered into a $15 million registered direct offering of pre-funded warrants to bolster working capital.
🚩 Red Flags
- Delisting notice: Failure to meet Nasdaq's minimum bid price requirement ($1.00).
- Potential for a reverse stock split to regain compliance if the share price does not recover.
- Significant dilution potential from the issuance of 27.2 million pre-funded warrants at $0.55 per share.
📋 Key Facts
- Received Nasdaq deficiency letter on January 8, 2024, due to stock closing below $1.00 for 30 consecutive business days.
- Company has a compliance period until July 8, 2024, to regain the $1.00 minimum bid price.
- Entered into a securities purchase agreement for a registered offering of pre-funded warrants.
- The offering involves up to 27,272,727 shares at a price of $0.55 per share (via warrant formula).
- Expected gross proceeds from the offering are approximately $15.0 million.
- Warrants have an exercise price of $0.0001 and no expiration date.
Atara Biotherapeutics announced a significant workforce reduction affecting approximately 25% of its employees and the departure of its Chief Medical Officer. The company expects to incur $4.5 million in severance costs related to this restructuring.
🚩 Red Flags
- Significant workforce reduction (25% of staff) often indicates cost-cutting measures due to liquidity or strategic shifts.
- Departure of a key executive officer (Chief Medical Officer).
- Multiple 8-K items in a single filing (Restructuring + Officer Departure).
📋 Key Facts
- Workforce reduction impacts approximately 25% of current employees, expected to be completed by May 2024.
- Estimated $4.5 million in total charges for severance and related benefits.
- Chief Medical Officer Manher (AJ) Joshi will depart effective February 2, 2024.
- Dr. Joshi will enter a consulting agreement through January 31, 2025, at $3,000/month plus hourly fees for excess hours.
- Dr. Joshi is entitled to an additional $185,000 upon FDA approval of the biologics license application for tabelecleucel.